-
1
-
-
0030953045
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
-
Lennernäs, H., Fager, G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet 1997, 32: 403-25.
-
(1997)
Clin Pharmacokinet
, vol.32
, pp. 403-425
-
-
Lennernäs, H.1
Fager, G.2
-
2
-
-
0035023185
-
Clinical pharmacokinetics of fluvastatin
-
Scripture, C.D., Pieper, J.A. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001, 40: 263-81.
-
(2001)
Clin Pharmacokinet
, vol.40
, pp. 263-281
-
-
Scripture, C.D.1
Pieper, J.A.2
-
3
-
-
0031664847
-
Pharmacokinetic studies on CI-981 (1): Absorption, distribution and excretion in rats following single oral or intravenous administration
-
Nemoto, H., Ebine, H., Ohzone, Y. et al. Pharmacokinetic studies on CI-981 (1): Absorption, distribution and excretion in rats following single oral or intravenous administration. Jpn Pharmacol Ther 1998, 26: 65-77.
-
(1998)
Jpn Pharmacol Ther
, vol.26
, pp. 65-77
-
-
Nemoto, H.1
Ebine, H.2
Ohzone, Y.3
-
5
-
-
0033758172
-
NK-104: A novel synthetic HMG-CoA reductase inhibitor
-
Kajinami, K., Mabuchi, H., Saito, Y. NK-104: A novel synthetic HMG-CoA reductase inhibitor. Exp Opin Invest Drugs 2000, 9: 2653-61.
-
(2000)
Exp Opin Invest Drugs
, vol.9
, pp. 2653-2661
-
-
Kajinami, K.1
Mabuchi, H.2
Saito, Y.3
-
6
-
-
0033831429
-
Clinical pharmacokinetics of cerivastatin
-
Mück, W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000, 39: 99-116.
-
(2000)
Clin Pharmacokinet
, vol.39
, pp. 99-116
-
-
Mück, W.1
-
7
-
-
0012609279
-
Phase I studies of HR780, an inhibitor of HMG-CoA reductase
-
Nakaya, N., Maeda, A., Irie, N., Ujita, S., Hayashi, T., Kobayashi, K. Phase I studies of HR780, an inhibitor of HMG-CoA reductase. Atherosclerosis 1994, 109: 254.
-
(1994)
Atherosclerosis
, vol.109
, pp. 254
-
-
Nakaya, N.1
Maeda, A.2
Irie, N.3
Ujita, S.4
Hayashi, T.5
Kobayashi, K.6
-
9
-
-
0034495168
-
Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetic events
-
Hatanaka, T. Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000, 39: 397-412.
-
(2000)
Clin Pharmacokinet
, vol.39
, pp. 397-412
-
-
Hatanaka, T.1
-
10
-
-
12244297486
-
Merck
-
Whitehouse Station, NJ, USA. September
-
Merck. Zocor® package insert (simvastatin). Whitehouse Station, NJ, USA. September 2000.
-
(2000)
Zocor® Package Insert (Simvastatin)
-
-
-
11
-
-
0031764986
-
NK-104
-
Sorbera, L.A., Leeson, P.A., Castaner, J. NK-104. Drugs Fut 1998, 23: 847.
-
(1998)
Drugs Fut
, vol.23
, pp. 847
-
-
Sorbera, L.A.1
Leeson, P.A.2
Castaner, J.3
-
13
-
-
0032805692
-
New insights into the pharmacodynamic and pharmacokinetic properties of statins
-
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84: 413-28.
-
(1999)
Pharmacol Ther
, vol.84
, pp. 413-428
-
-
Corsini, A.1
Bellosta, S.2
Baetta, R.3
Fumagalli, R.4
Paoletti, R.5
Bernini, F.6
-
14
-
-
0035825928
-
Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (1)
-
McTaggart, F., Buckett, L., Davidson, R. et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (1). Am J Cardiol 2001, 87 (Suppl 1): 28-32.
-
(2001)
Am J Cardiol
, vol.87
, Issue.SUPPL. 1
, pp. 28-32
-
-
McTaggart, F.1
Buckett, L.2
Davidson, R.3
-
15
-
-
0026814425
-
Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans
-
Pentikainen, P.J., Saraheimo, M., Schwartz, J.I. et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992, 32: 136-40.
-
(1992)
J Clin Pharmacol
, vol.32
, pp. 136-140
-
-
Pentikainen, P.J.1
Saraheimo, M.2
Schwartz, J.I.3
-
16
-
-
0025076205
-
Disposition of fluvastatin, and inhibitor of HMG-CoA reductase, in mouse, rat, dog, and monkey
-
Tse, F.L.S., Smith, H.T., Ballard, F.H., Nicoletti, J. Disposition of fluvastatin, and inhibitor of HMG-CoA reductase, in mouse, rat, dog, and monkey. Biopharm Drug Dispos 1990, 11: 519-31.
-
(1990)
Biopharm Drug Dispos
, vol.11
, pp. 519-531
-
-
Tse, F.L.S.1
Smith, H.T.2
Ballard, F.H.3
Nicoletti, J.4
-
17
-
-
0027378356
-
Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human
-
Halpin, R.A., Ulm, E.H., Till, A.E. et al. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 1993, 21: 1003-11.
-
(1993)
Drug Metab Dispos
, vol.21
, pp. 1003-1011
-
-
Halpin, R.A.1
Ulm, E.H.2
Till, A.E.3
-
18
-
-
0029853471
-
Cerivastatin, a new inhibitor of HMG-CoA reductase-pharmacokinetics in rats and dogs
-
Steinke, W., Yamashita, S., Tabei, M. et al. Cerivastatin, a new inhibitor of HMG-CoA reductase-pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 1996, 24 (Suppl): 7-27.
-
(1996)
Jpn Pharmacol Ther
, vol.24
, Issue.SUPPL.
, pp. 7-27
-
-
Steinke, W.1
Yamashita, S.2
Tabei, M.3
-
20
-
-
0026668094
-
Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys
-
Komai, T., Kawai, K., Tokui, T. et al. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 1992, 17: 103-13.
-
(1992)
Eur J Drug Metab Pharmacokinet
, vol.17
, pp. 103-113
-
-
Komai, T.1
Kawai, K.2
Tokui, T.3
-
21
-
-
0029846754
-
Tissue-selective uptake of pravastatin in rats: Contribution of a specific carrier-mediated uptake system
-
Yamazaki, M., Tokui, T., Ishigam, M., Sugiyama, Y. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm Drug Dispos 1996, 17: 775-89.
-
(1996)
Biopharm Drug Dispos
, vol.17
, pp. 775-789
-
-
Yamazaki, M.1
Tokui, T.2
Ishigam, M.3
Sugiyama, Y.4
-
22
-
-
0024513882
-
The physiological disposition of lovastatin
-
Duggan, D.E., Chen, I.-W., Bayne, W.F. et al. The physiological disposition of lovastatin. Drug Metab Dispos 1989, 17: 166-73.
-
(1989)
Drug Metab Dispos
, vol.17
, pp. 166-173
-
-
Duggan, D.E.1
Chen, I.-W.2
Bayne, W.F.3
-
23
-
-
0025240977
-
Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug
-
Vickers, S., Duncan, C.A., Chen, I.-W., Rosegay, A., Duggan, D.E. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990a, 18: 138-45.
-
(1990)
Drug Metab Dispos
, vol.18
, pp. 138-145
-
-
Vickers, S.1
Duncan, C.A.2
Chen, I.-W.3
Rosegay, A.4
Duggan, D.E.5
-
24
-
-
0034961288
-
Drug interaction between simvastatin and itraconazole in male and female rats
-
Ishigami, M., Kawabata, K., Takasaki, W. et al. Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab Dispos 2001, 29: 1068-72.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 1068-1072
-
-
Ishigami, M.1
Kawabata, K.2
Takasaki, W.3
-
25
-
-
0032791745
-
Metabolism and excretion of atorvastatin in rats and dogs
-
Black, A.E., Hayes, R.N., Roth, B.D., Woo, P., Woolf, T.F. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 1999, 27: 916-23.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 916-923
-
-
Black, A.E.1
Hayes, R.N.2
Roth, B.D.3
Woo, P.4
Woolf, T.F.5
-
26
-
-
0032937343
-
The 3- hydroxy- 3-methylglutaryl, coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
-
Fischer, V., Johanson, L., Heitz, F. et al. The 3- hydroxy- 3-methylglutaryl, coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999, 27: 410-6.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 410-416
-
-
Fischer, V.1
Johanson, L.2
Heitz, F.3
-
27
-
-
0032970752
-
Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection
-
Kojima, J., Fujino, H., Yosimura, M., Morikawa, H., Kimata, H. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatography 1999, 724: 173-80.
-
(1999)
J Chromatography
, vol.724
, pp. 173-180
-
-
Kojima, J.1
Fujino, H.2
Yosimura, M.3
Morikawa, H.4
Kimata, H.5
-
28
-
-
0032962809
-
Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
-
Shiomi, M., Ito, T. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999, 126: 961-8.
-
(1999)
Br J Pharmacol
, vol.126
, pp. 961-968
-
-
Shiomi, M.1
Ito, T.2
-
29
-
-
0002549759
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG- CoA reductase (4): Interspecies variation in laboratory animals and humans
-
Fujino, H., Kojima, J., Yamada, Y., Kanda, H., Kimata, H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG- CoA reductase (4): Interspecies variation in laboratory animals and humans. Xenobiotic Metab Dispos 1999a, 14: 79-91.
-
(1999)
Xenobiotic Metab Dispos
, vol.14
, pp. 79-91
-
-
Fujino, H.1
Kojima, J.2
Yamada, Y.3
Kanda, H.4
Kimata, H.5
-
30
-
-
0026596619
-
Absorption and disposition of fluvastatin, and inhibitor of HMG-CoA reductase, in the rabbit
-
Tse, F.L.S., Labbadia, D. Absorption and disposition of fluvastatin, and inhibitor of HMG-CoA reductase, in the rabbit. Biopharm Drug Dispos 1992, 13: 285-94.
-
(1992)
Biopharm Drug Dispos
, vol.13
, pp. 285-294
-
-
Tse, F.L.S.1
Labbadia, D.2
-
31
-
-
0031845787
-
Metabolism and excretion studies in mouse after single and multiple oral doses of the 3 hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin
-
Black, A.E., Sinz, M.W., Hayes, R.N., Woolf, T.F. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3 hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 1998, 26: 755-63.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 755-763
-
-
Black, A.E.1
Sinz, M.W.2
Hayes, R.N.3
Woolf, T.F.4
-
32
-
-
0000332988
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (I): Absorption, distribution, metabolism and excretion in rats
-
Kimata, H., Fujino, H., Koide, T., Yamada, Y., Tsunenari, Y., Yanagawa, Y. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (I): Absorption, distribution, metabolism and excretion in rats. Xenobiotic Metab Dispos 1998, 13: 484-98.
-
(1998)
Xenobiotic Metab Dispos
, vol.13
, pp. 484-498
-
-
Kimata, H.1
Fujino, H.2
Koide, T.3
Yamada, Y.4
Tsunenari, Y.5
Yanagawa, Y.6
-
33
-
-
0028242843
-
High lipophiliicty decreases drug transport across intestinal epithelial cells
-
Wils, P., Warnery, A., Phunga-Ba, V., Legrain, S., Scherman, D. High lipophiliicty decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther 1994, 269: 654-8.
-
(1994)
J Pharmacol Exp Ther
, vol.269
, pp. 654-658
-
-
Wils, P.1
Warnery, A.2
Phunga-Ba, V.3
Legrain, S.4
Scherman, D.5
-
34
-
-
0026567257
-
Hepatic and nonhepatic sterol synthesis and tissue distribution following adminis- tration of a liver selective HMG-CoA reductase inhibitor, CI-981. Comparison with selected HMG-CoA reductase inhibitors
-
Bocan, T.M.A., Ferguson, E., McNally, W. et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following adminis- tration of a liver selective HMG-CoA reductase inhibitor, CI-981. Comparison with selected HMG-CoA reductase inhibitors. Biochimica Biophysica Acta 1992, 1123: 133-44.
-
(1992)
Biochimica Biophysica Acta
, vol.1123
, pp. 133-144
-
-
Bocan, T.M.A.1
Ferguson, E.2
McNally, W.3
-
35
-
-
0026641368
-
Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat
-
Koga, T., Fukuda, K., Shimada,Y., Fukami, M., Koike, H., Tsujita, Y. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 1992, 209: 315-19.
-
(1992)
Eur J Biochem
, vol.209
, pp. 315-319
-
-
Koga, T.1
Fukuda, K.2
Shimada, Y.3
Fukami, M.4
Koike, H.5
Tsujita, Y.6
-
36
-
-
0024508358
-
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo
-
Germershausen, J.I., Hunt, V.M., Bostedor, R.G., Bailey, P.J., Karkas, J.D., Alberts, A.W. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 1989, 158: 667-75.
-
(1989)
Biochem Biophys Res Commun
, vol.158
, pp. 667-675
-
-
Germershausen, J.I.1
Hunt, V.M.2
Bostedor, R.G.3
Bailey, P.J.4
Karkas, J.D.5
Alberts, A.W.6
-
37
-
-
0032456123
-
Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin
-
Hatanaka, T., Honda, S., Sasaki, S., Katayama, K., Koizumi, T. Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin. J Pharmacokinet Biopharm 1998, 26: 329-47.
-
(1998)
J Pharmacokinet Biopharm
, vol.26
, pp. 329-347
-
-
Hatanaka, T.1
Honda, S.2
Sasaki, S.3
Katayama, K.4
Koizumi, T.5
-
38
-
-
0027723663
-
Terasaki, T Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier
-
Tsuji, A., Saheki, A., Tamai, I., Terasaki, T Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993, 267: 1085-90.
-
(1993)
J Pharmacol Exp Ther
, vol.267
, pp. 1085-1090
-
-
Tsuji, A.1
Saheki, A.2
Tamai, I.3
-
39
-
-
0000332994
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (3): Foeto-placental transfer and mammary excretion after oral administration in rats
-
Fujino, H., Morikawa, S., Kanda, H., Kimata, H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (3): Foeto-placental transfer and mammary excretion after oral administration in rats. Xenobiotic Metab Dispos 1998, 13: 508-15.
-
(1998)
Xenobiotic Metab Dispos
, vol.13
, pp. 508-515
-
-
Fujino, H.1
Morikawa, S.2
Kanda, H.3
Kimata, H.4
-
40
-
-
0031660328
-
Pharmacokinetic studies on CI-981 (2): Absorption, distribution and excretion following repeated oral administration, and placental transfer and transfer to milk and suckling pups following single oral administration
-
Nemoto, H., Takao, A., Noguchi, T. et al. Pharmacokinetic studies on CI-981 (2): Absorption, distribution and excretion following repeated oral administration, and placental transfer and transfer to milk and suckling pups following single oral administration. Jpn Pharmacol Ther 1998, 26: 79-96.
-
(1998)
Jpn Pharmacol Ther
, vol.26
, pp. 79-96
-
-
Nemoto, H.1
Takao, A.2
Noguchi, T.3
-
41
-
-
0000626919
-
ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems
-
McCormick, A.D., McKillop, D., Butters, C.J. et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. J Clin Pharmacol 2000, 40: 1045-65.
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1045-1065
-
-
McCormick, A.D.1
McKillop, D.2
Butters, C.J.3
-
42
-
-
0031843611
-
Biotransformation of cerivastatin in mice, rats, and dogs in vivo
-
Boberg, M., Angerbauer, R., Kanhaia, W.K. et al. Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metab Dispos 1998, 26: 640-52.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 640-652
-
-
Boberg, M.1
Angerbauer, R.2
Kanhaia, W.K.3
-
43
-
-
0028986096
-
Disposition of [3H] fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae
-
Tse, F.L.S., Dain, J.G., Kalafsky, G. Disposition of [3H] fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. Biopharm Drug Dispos 1995, 16: 211-19.
-
(1995)
Biopharm Drug Dispos
, vol.16
, pp. 211-219
-
-
Tse, F.L.S.1
Dain, J.G.2
Kalafsky, G.3
-
46
-
-
0001224909
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human
-
Fujino, H., Yamada, I., Kojima, J., Hirano, M., Matsumoto, H., Yoneda, M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobiotic Metab Dispos 1999, 14: 415-24.
-
(1999)
Xenobiotic Metab Dispos
, vol.14
, pp. 415-424
-
-
Fujino, H.1
Yamada, I.2
Kojima, J.3
Hirano, M.4
Matsumoto, H.5
Yoneda, M.6
-
47
-
-
0032914056
-
Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile
-
Kojima, J., Fujino, H., Abe, H., Yosimura, M., Kanda, H., Kimata, H. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 1999, 22: 142-50.
-
(1999)
Biol Pharm Bull
, vol.22
, pp. 142-150
-
-
Kojima, J.1
Fujino, H.2
Abe, H.3
Yosimura, M.4
Kanda, H.5
Kimata, H.6
-
48
-
-
0025316348
-
In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase
-
Vickers, S., Duncan, C.A., Vyas, K.P. et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990b, 18: 476-83.
-
(1990)
Drug Metab Dispos
, vol.18
, pp. 476-483
-
-
Vickers, S.1
Duncan, C.A.2
Vyas, K.P.3
-
49
-
-
0026316001
-
Studies on the metabolic inversion of the 6′ chiral center of simvastatin
-
Vickers, S., Duncan, C.A. Studies on the metabolic inversion of the 6′ chiral center of simvastatin. Biochem Biophys Res Comnmn 1991, 181: 1508-15.
-
(1991)
Biochem Biophys Res Comnmn
, vol.181
, pp. 1508-1515
-
-
Vickers, S.1
Duncan, C.A.2
-
50
-
-
0034837905
-
β-oxidation of simvastatin in mouse liver preparations
-
Prueksaritanont, T., Ma, B., Fang, X., Subramanian, R., Yu, J., Lin, J.H. β-oxidation of simvastatin in mouse liver preparations. Drug Metab Dispos 2001, 29: 1251-5.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 1251-1255
-
-
Prueksaritanont, T.1
Ma, B.2
Fang, X.3
Subramanian, R.4
Yu, J.5
Lin, J.H.6
-
51
-
-
0025216735
-
Biotransformation of lovastatin. 1. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse
-
Vyas, K.P., Kari, P.H., Pitzenberger, S.M. et al. Biotransformation of lovastatin. 1. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. Drug Metab Dispos 1990a, 18: 203-11.
-
(1990)
Drug Metab Dispos
, vol.18
, pp. 203-211
-
-
Vyas, K.P.1
Kari, P.H.2
Pitzenberger, S.M.3
-
52
-
-
0025248279
-
Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes arid involvement of cytochrome P-450 in dehydrogenation of lovastatin
-
Vyas, K.P., Kari, P.H., Prakash, S.R., Duggan, D.E. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes arid involvement of cytochrome P-450 in dehydrogenation of lovastatin. Drug Metab Dispos 1990, 18: 218-22.
-
(1990)
Drug Metab Dispos
, vol.18
, pp. 218-222
-
-
Vyas, K.P.1
Kari, P.H.2
Prakash, S.R.3
Duggan, D.E.4
-
53
-
-
0023687124
-
Metabolism of lovastatin by rat and human liver microsomes in vitro
-
Greenspan, M.D., Yudkovitz, J.B., Alberts, A.W., Argenbright, L.S., Arison, B.H., Smith, J.L. Metabolism of lovastatin by rat and human liver microsomes in vitro. Drug Metab Dispos 1988, 16: 678-82.
-
(1988)
Drug Metab Dispos
, vol.16
, pp. 678-682
-
-
Greenspan, M.D.1
Yudkovitz, J.B.2
Alberts, A.W.3
Argenbright, L.S.4
Arison, B.H.5
Smith, J.L.6
-
54
-
-
12244287147
-
Differences in rate of hydrolysis of HMG-CoA reductase inhibitors in human and animal tissues
-
Fukuo, Y., Akaishi, H., Honda, H. et al. Differences in rate of hydrolysis of HMG-CoA reductase inhibitors in human and animal tissues. Atherosclerosis 1994, 109: 254.
-
(1994)
Atherosclerosis
, vol.109
, pp. 254
-
-
Fukuo, Y.1
Akaishi, H.2
Honda, H.3
-
55
-
-
0026093336
-
Metabolism of pravastatin sodium in isolated rat hepatocytes. II. Structure elucidation of the metabolites by n.m.r. spectroscopy
-
Nakamura, T., Yoda, K,., Kuwano, H. et al. Metabolism of pravastatin sodium in isolated rat hepatocytes. II. Structure elucidation of the metabolites by n.m.r. spectroscopy. Xenobiotica 1991, 21: 277-303.
-
(1991)
Xenobiotica
, vol.21
, pp. 277-303
-
-
Nakamura, T.1
Yoda, K.2
Kuwano, H.3
-
56
-
-
0026749181
-
Metabolism of pravastatin sodium in isolated rat hepatocytes. 1. Glutathione conjugate formation reaction
-
Muramatsu, S., Miyaguchi, K., Iwabuchi, H. et al. Metabolism of pravastatin sodium in isolated rat hepatocytes. 1. Glutathione conjugate formation reaction. Xenobiotica 1992, 22: 487-98.
-
(1992)
Xenobiotica
, vol.22
, pp. 487-498
-
-
Muramatsu, S.1
Miyaguchi, K.2
Iwabuchi, H.3
-
57
-
-
0012528472
-
Chronic toxicokinetic profiles of atorvastatin in beagle dogs
-
Shum,Y.Y., Walter, G., Huang, N.-J., Rothwell, C., Whitfield, L.R. Chronic toxicokinetic profiles of atorvastatin in beagle dogs. 12th Int Symp Drugs Affecting Lipid Metab 1995, 100.
-
(1995)
12th Int Symp Drugs Affecting Lipid Metab
, pp. 100
-
-
Shum, Y.Y.1
Walter, G.2
Huang, N.-J.3
Rothwell, C.4
Whitfield, L.R.5
|